Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MRI-Guided radiation may improve cervical cancer treatment

NCT ID NCT03005743

Disease control Sponsor: Tata Memorial Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This large phase III trial tested whether using MRI scans to guide internal radiation (brachytherapy) works better than the traditional X-ray method for women with locally advanced cervical cancer. Over 1,000 participants received either MRI-based or X-ray-based brachytherapy. The goal was to see if MRI guidance improves tumor control and reduces severe side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiation therapy (brachytherapy)
What this could lead to
If MRI-guided brachytherapy proves better, it could become the new standard for treating locally advanced cervical cancer, offering better tumor control and fewer long-term side effects.
What could go wrong
This trial is completed but results are not yet widely implemented. MRI-guided brachytherapy requires specialized equipment and training, so it may not be available everywhere. Also, individual results vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,050 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2016

Finished

May 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Cancer of the uterine cervix considered suitable for curative treatment with definitive radio-(chemo) therapy including MRI guided Brachytherapy. * Positive biopsy showing squamous-cell carcinoma, adenocarcinoma or adeno-squamous cell carcinoma of the uterine cervix. * Stage IIB/IIIB according to FIGO and tumor node metastasis (TNM) guidelines * Suitable for Brachytherapy boost * MRI of pelvis at diagnosis is performed * MRI, Computed Tomography (CT) or Positron Emission Tomography (PET) -CT of the retroperitoneal space and abdomen at diagnosis is performed to rule out Para-aortic lymph node metastasis. * Patient informed consent * Pre-treatment Haemoglobin level \>10 g/dL Exclusion Criteria: * Other primary malignancies except carcinoma in situ of the cervix and basal cell carcinoma of the skin. * Metastatic disease * Patients with para-aortic metastatic nodes (stage IVB) to the level of L2 vertebra or further dissemination * Previous pelvic or abdominal radiotherapy * Previous total or partial hysterectomy * Combination of preoperative radiotherapy with surgery * Patients receiving BT only * Patients receiving EBRT only * Patients receiving neoadjuvant chemotherapy * Contraindications to MRI * Contraindications to BT * Active infection or severe medical condition endangering treatment delivery. * Pregnant, lactating or childbearing potential without adequate contraception

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical cancer

Contacts and locations

Locations

  • Tata Memorial Hospital

    Mumbai, Maharashtra, 400012, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.